This 8-week , randomized ( 1:1 ) , double-blind , placebo-controlled , parallel-group , fixed-dose study conducted from January 2012 to February 2013 compared vilazodone 40 mg/d with placebo in outpatients with DSM-IV-TR-diagnosed MDD .